%PDF-1.7 % 12 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20191114064144+01'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 13 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /PZ 1 >> endobj 13 0 obj <> stream x[ےF}+dK<9n$lX iHZT{=3mC.mgO|o5=o\O9<`|7//7 f{`"Gxˏ>_j`|Ȝѱ3Ůap#s#OqVQt>Dqő}O )QxQ4X/xlⒾ3 ET<5ےgfqLx|MWg'udg AD6OTBbjRFңBBg i\T JXܠ:D!;Ɓ zW5 0`^[skn##p7 O|%eUwM5a% *%^ bg WE1kF ʆJ2aX!I-tEb]kٶiG%pc. 9,$+Hĥ]!v ]%Hxkp,1DEmr sðPoW`x4h(xөs (QU,7b^**6GsmSv޽8O *Ǹh='k܊^qq@dڒ61. ܅!3n4{Qonj9VTh珉S=& 0.QcNCxv7._fNcmp/ VV1M,ѷhU;\5KR\ 'ti;&dEp]k6.\`6pSm.&bF^ZvwlSlf4/MwyH/*=iꡭ w| ;O_Ȝ:\M^sm/ І>_˖xBHq0K 4f{If9NUQM瑫GC$i%C0idHsyHz/Ų B]vm"]Uf7Ɖ2ie#ֈ`nшV1.^{@#]WtlA34XJaum$io5͎˿(0`Vwlt;1к%k4% 3^8Ha:F{yu jzM[6١?pb:pc̽iӶ}m72ȎE9{X6\EUvE+3٤ֿiP2&e 'r0\oel~lu ]D,d "/M6xhcEF7 H!˥L1։QE~4g  `> /Annots [ 5 0 R 6 0 R ] /PZ 1 >> endobj 15 0 obj <> stream x\˖6+j399j/Qjm39I3^$Y$$M J.0OvۏٲcKHIuqV0CB  <G=8IKxtz/|['E _ QOh`zJxvٻ|1j1 ~"=;EEi a$r^xtJyh-L2Q.K㲫9ldbоFh`eh)JN9x!Wи9-wxq^-JqCgj:ȓ"7N s8rm0:&"IkG3.#3dRy|+֡<|pTp/t9AiP,aqeAs.+[Nah#Xo֔ eAF9F@0A:΃Y& Sͪۢڛ2'BOPȐ=g^ű3}9!}]:Fk㣪P),5\a՚`eZQ~nj?(̼/w*L+ u$I*EZOBD?\4u-b>e( Y/I Q2_ ڈ>8;HsKݟR]bdAy_Yl_|h ] LUx$YS0$ U%1Y[n(cqҎ8ӡhEӰb[;b!\JNB<*Y6HR) ٫kZ̩ڰ3^ɺ *ĺQdljDc\3i2L ,Ba: }1|; uJƨ<=,Ja嘩R5RDA f>走ECC(wӧH2!J ֞m@Mco^:1I&wK(;6 F7=dkss0`]1Dيu b7(aRG_ּ e}K+CvT6"޸ʌ6!|ܴd`I5"r Z7FO&PɁT)=6NCTQM1 Bӥ]<`W4LS/'&[Eq߾D;'N8Sӥ^$E.;[3Q[ y-02-z]>4x4 mſ k+T-P4Lz;(iM/&›<4: MS݉$Ociv.d5Pj\19#nD_c.n=V\PpZ'$Ov$%PPBc.z 8s%8DF p>< kUjnV!7h6v'ࢧjhN 'W~l.sMMrF\`މSO uj{( R'c>0DT$6\]eE ^Odf+}KV;?n ݹn$KCÎڌ~Gp=rgZ,[z=!>zOH&BA=c4k,w焈L }(X8~a+C9/C~_%,Qdٯ8<ֺ4yem/90=<ٰ/'Arxg1صpxK?yNwvp;֡rϏ~}8V]rFoAtqD!.\7mACi߬;k^V6z^}I ̉@R=ui*/t\+twlWfLm^mi6o?FK{l\(, 5}˙Nۆq'#,"qYfI8IVз /pR_6e+vG} n" (-kn_] wV&I(L_b8ѱ|;~ԗ17Ύ~73,IgjGC~ Sͮ:4(i  Hb*^wbD%/e; [ãwA,MzsV CfhLa4rr=WAFOZZI4zPAG@Y.mɇw(6+[kY`-ϭ endstream endobj 16 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20191114064144+01'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 17 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 7 0 R 8 0 R 9 0 R 10 0 R 11 0 R ] /PZ 1 >> endobj 17 0 obj <> stream x[r6}WS4/niI4t>@$$"& - ,˪8c&')RgoH F!B!0ώWOOIt맄]{N ߶@?;1cZy^>xn+][onǭ=Q Gc%>`<F0HFQ4i|\.Ū,jqH'Q懊kTJч4H%[43BVAn0$G%(Hj sB%w nxp8D1E5`}ukY6Vo4jWϊ.l ȱoźd%< wJߚ2[O`??QKNMǷQrAPCh&L4U+yn%-(NmЁS%g"eg`$OqG.V H<g!էA @5>qS~4Ge (b.xփ*S@y )?H; ,Nj!^S~ "aq c-FFVhL $f@U)~()09zNԷ=Q޶Q@F^ 2N;TxYrŹlt@ Sl MMf E/XzrI}9kZԼd)4)PŗŻ8qXSAI E 5ux2g=(RR,$/c ԌWHӋ&Z HVa,R*fSYm?O 9C94ZAdD)dYs#J; +Je!޿,&fv3~ YBj%bLn ћ)2w //H55 قҢH8QM%.nY}h "Bx @.,9nO}lڰe఩yVҐ P6O2e42Mjc֜⫍[tQĠH}Pڨev+-g&*ca em#@]~i`)eQbeINdj} c4uG]Yjk2W`R7$)old>uA 8li!PU ƒ{_ڠǣvsX| ~[lPN`);O7;>4>q s>r8}ȣa{&I l'Ɠ7a4ǣAtGuPS^KTz+D7R_tvTvPHyJEmKH{'4((RQ:5Jrf_nf˖L"_3W4OT=_^OFSWNhe[ GϞ=>_`xM5-(k86WRHI\/fFOh+ 0tutN }j1JsV-xjHb~ lytbQI|yoR Wj.YuJ2 !2V"݃u3फ़ W}pZ8h8l r?wPJC5+['WݸۦT{ͰsRBX 6+G4\)&PӰhGxuSp9eaNK.C}ջFPh9Z<I΄kڶ3b>g V 'lϰfVx `S@B%t\[+X4Lpۣ>zo$r35D[߾»KxXRP/[֫5sRMҮq)HԥSمh 1>:md3vA Ӻ)9QOl+W#kYmp?(lC5gu+KWi/&%|tR;o ؛ %`lxqlO%W.>:9~olkҤu6}[˃?w>}^x endstream endobj 1 0 obj << /Type /Pages /Kids [ 12 0 R 14 0 R 16 0 R ] /Count 3 >> endobj 3 0 obj <> endobj 4 0 obj <> endobj 18 0 obj <> /Resources <> /Font <> /ExtGState <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 848 >> stream xWmO0^c$H (똆AIC|J(ՠemIªل׹Gdw7>9<GkDžaW$<"H2|R(29:9$^-e>..y.Gd:|VCd` ')ɮB(TEҒ %% E֙ J,$BDO&D>MH0-6=C.h&CfR\ X+b :Nic*k+ p.}&xs|"8 n,v )W-6o=߸hNftK:M[ۀr!e\KeAky$RP<⺍pxup8>H  M{qI3_w,縲eGfNՑmna.hȓjYU,b\2OuyZ6#sC͚3gkriӲ ly#4]kDfu |w*lm O镸080iIsӵһ%7/i\XJ.̚5K5jM9aq'wqh%Q*i gyQ(p]5'CԫkSuRCln_*9{.+|FAqp-Pg*O hsRՎSJ&`1U$GBHB-K5NюG~?Rh#%SkC3a-r"7αը $O+ o endstream endobj 25 0 obj <> /Resources <> /Font <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 220 >> stream x]M0EԅIтUqEڅ̿7.:Ãۼ{?bb_"YiFgTT&IF |Sk=(PB{U!Z]?s{7mCwoTbV DH)iRHK 4 A&J0;*UaVj&T]Y-v|OɄzUx5>w I endstream endobj 24 0 obj <> endobj 23 0 obj <> endobj 30 0 obj [250 0 0 0 0 0 0 0 0 0 0 564 0 333 250 0 500 500 500 500 500 0 500 500 500 500 0 0 0 0 0 0 921 0 0 0 722 611 556 722 722 0 0 0 0 889 0 0 556 0 667 556 0 0 0 0 0 0 611 0 0 0 0 0 0 444 500 444 500 444 0 0 500 278 0 500 278 778 500 500 500 0 333 389 278 500 500 722 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 ] endobj 29 0 obj <> endobj 22 0 obj <> stream x  Om7^ Oa endstream endobj 31 0 obj <> stream x nH@o endstream endobj 21 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 20 0 obj <> stream x  Om783  endstream endobj 32 0 obj <> stream x nH@paX endstream endobj 19 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > endobj 34 0 obj [250 ] endobj 33 0 obj <> endobj 27 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 26 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > /XObject <> >> endobj 5 0 obj <> /H /I>> endobj 6 0 obj <> /H /I>> endobj 7 0 obj <> /H /I>> endobj 8 0 obj <> /H /I>> endobj 9 0 obj <> /H /I>> endobj 10 0 obj <> /H /I>> endobj 11 0 obj <> /H /I>> endobj 35 0 obj << /Title (Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management) /Author (Daiichi Sankyo) /Subject (Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management) /Creator (TCPDF) /Producer (TCPDF 6.2.26 \(http://www.tcpdf.org\)) /CreationDate (D:20191114064144+01'00') /ModDate (D:20191114064144+01'00') /Trapped /False >> endobj 36 0 obj << /Type /Metadata /Subtype /XML /Length 4497 >> stream application/pdf Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management Daiichi Sankyo Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management 2019-11-14T06:41:44+01:00 TCPDF 2019-11-14T06:41:44+01:00 2019-11-14T06:41:44+01:00 TCPDF 6.2.26 (http://www.tcpdf.org) uuid:99050f86-e80e-1154-aed0-6f82f411d44c uuid:99050f86-e80e-1154-aed0-6f82f411d44c http://ns.adobe.com/pdf/1.3/ pdf Adobe PDF Schema http://ns.adobe.com/xap/1.0/mm/ xmpMM XMP Media Management Schema internal UUID based identifier for specific incarnation of a document InstanceID URI http://www.aiim.org/pdfa/ns/id/ pdfaid PDF/A ID Schema internal Part of PDF/A standard part Integer internal Amendment of PDF/A standard amd Text internal Conformance level of PDF/A standard conformance Text endstream endobj 37 0 obj << /Type /Catalog /Version /1.7 /Pages 1 0 R /Names << >> /ViewerPreferences << /Direction /L2R >> /PageLayout /SinglePage /PageMode /UseNone /OpenAction [12 0 R /FitH null] /Metadata 36 0 R >> endobj xref 0 38 0000000000 65535 f 0000008492 00000 n 0000045597 00000 n 0000008566 00000 n 0000008672 00000 n 0000045737 00000 n 0000046019 00000 n 0000046299 00000 n 0000046581 00000 n 0000046811 00000 n 0000047044 00000 n 0000047284 00000 n 0000000015 00000 n 0000000467 00000 n 0000002662 00000 n 0000003138 00000 n 0000005901 00000 n 0000006397 00000 n 0000008783 00000 n 0000020467 00000 n 0000019674 00000 n 0000012004 00000 n 0000011444 00000 n 0000010591 00000 n 0000010535 00000 n 0000010003 00000 n 0000037097 00000 n 0000029427 00000 n 0000028967 00000 n 0000011192 00000 n 0000010777 00000 n 0000011751 00000 n 0000020155 00000 n 0000029175 00000 n 0000029152 00000 n 0000047502 00000 n 0000048301 00000 n 0000052881 00000 n trailer << /Size 38 /Root 37 0 R /Info 35 0 R /ID [ <99050f86e80e1154aed06f82f411d44c> <99050f86e80e1154aed06f82f411d44c> ] >> startxref 53091 %%EOF

Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management

Management strategies in the new ESC Atrial Fibrillation Guidelines align with those identified in the Report to address the urgent public health issue

Munich, Germany (26 September, 2016) – Daiichi Sankyo Europe GmbH welcomes the publication of the new European Society of Cardiology (ESC) Management of Atrial Fibrillation Guidelines, which highlight the importance of preventing stroke and moving toward an integrated approach to patient care across healthcare systems.1 The guidelines echo recommendations from the Future of Anticoagulation Report2 which last year called for urgent action to reduce the impact of atrial fibrillation (AF) in Europe, for which prevalence is expected to at least double to nearly 18 million by 2060.3

The Future of Anticoagulation Report, featuring input from a panel of leading European medical, patient group and health economic experts, and researched and written by RAND Europe, identified the need for improved AF detection and diagnosis, through increased public awareness of AF and opportunistic screening.2 This recommendation is now recognised in the new ESC AF Guidelines, which place greater emphasis on early detection of AF and include evidence based support for opportunistic and targeted screening for AF.1 The Report further highlighted the need for continued improvement in patient stratification based on biomarkers,2 a point that is now specifically addressed in the Guidelines.1

The Report recommendations also call for health systems to align with current evidence on the effectiveness of therapies and other management interventions in AF related stroke prevention.2 In line with this and following recent treatment developments, the new Guidelines recommend non-VKA oral anticoagulants, or NOACs (including edoxaban, apixaban, dabigatran, and rivaroxaban) in preference to Vitamin K antagonists for stroke prevention in AF patients (class 1A recommendation, based on the level of evidence).1

Reflecting on advances in technology, both the Report and subsequently the Guidelines support the wider use of technology in the form of smartphone apps to support education and improved management for patients and healthcare professionals.1,2 The new ESC AF Guidelines also reflect the Report’s recommendation for an integrated approach to patient care; with guidance supporting the development of multidisciplinary AF teams, which encompass multiple levels of healthcare systems, and place patients at the forefront of care.1

“It’s difficult to overstate the impact that AF could have on healthcare systems in Europe over the next few decades,” said Trudie C. Lobban MBE, Founder & CEO of the Atrial Fibrillation Association and Steering Committee member of the Future of Anticoagulation Report. “AF is a condition that already claims thousands of lives and leaves many more severely disabled. We urgently need to see improvements in care for people with AF, and it’s promising to see that the findings from the Future of Anticoagulation Report are being recognised and that the new ESC AF Guidelines are meeting some of the needs identified.”

Awareness of AF and stroke prevention are at the heart of addressing the burden of this condition. Acute stroke is a common first presentation of AF, and one in five strokes are caused by AF.4 Furthermore, a third of people with AF will die as a result of their first stroke and those who survive are 50% more likely to be disabled or handicapped three months after the event.5 With costs associated with AF estimated at €26-30 billion per year,2 and its ever increasing prevalence, it is imperative that improvements are made now to turn the tide on this important healthcare issue.

“The Future of Anticoagulation Report is a valuable resource for stakeholders across Europe to inform on necessary changes needed to improve patient care” said Oliver Appelhans, Senior Vice President Head of Cardiovascular Products, Business Development & NPP at Daiichi Sankyo Europe GmbH. “We are proud to support the development of the Report, contributing to the existing breadth of knowledge in this area, and pleased to see important changes reflected in the new ESC AF Guidelines.”

To find out more about The Future of Anticoagulation Report, download it free from: http://www.rand.org/randeurope/research/projects/future-of-anticoagulation.html.

The ESC AF Guidelines are available to view at: eurheartj.oxfordjournals.org/content/early/2016/08/26/eurheartj.ehw210

About AF

AF is a condition where the heart beats irregularly and rapidly. When this happens, blood can pool and thicken in the chambers of the heart causing an increased risk of blood clots. These blood clots can break off and travel through the blood stream to the brain (or sometimes to another part of the body), where they have the potential to cause a stroke.6

AF is the most common type of heart rhythm disorder, and is associated with substantial morbidity and mortality.7 More than six million Europeans are diagnosed with AF, and this figure is expected to at least double over the next 50 years.3,4 Compared to those without AF, people with the arrhythmia have a 3-5 times higher risk of stroke.8 One in five of all strokes are as a result of AF.4

About the Future of Anticoagulation Report

The Future of Anticoagulation Report was published by RAND Europe and features input from 10 leading European medical, patient group and health economic experts.2 It provides short- and long-term recommendations to support improvements in AF awareness among the public and also informs policymakers, healthcare bodies and healthcare professionals on changes needed to improve AF management for patients.2 The Future of Anticoagulation initiative was supported financially and in kind by Daiichi Sankyo Europe.

About RAND Europe

RAND Europe is a not-for-profit research organisation that helps improve policy and decision making through research and analysis. Data collection, analysis and Report development were performed by RAND Europe in collaboration with an independent Steering Committee. The Future of Anticoagulation Report is located at: www.rand.org/randeurope/research/projects/future-of-anticoagulation.html. More information on RAND Europe can be found at www.randeurope.org.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.

Contact

Lydia Worms (Europe)
Daiichi Sankyo Europe GmbH
Edoxaban Communications & Product PR Europe

Lydia.Worms@daiichi-sankyo.eu

+49 (89) 7808751

Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.